NuCana plc (NASDAQ: NCNA) is 18.93% higher on its value in year-to-date trading and has touched a low of $3.81 and a high of $10.59 in the current 52-week trading range. The NCNA stock was last observed hovering at around $4.54 in the last trading session, with the day’s gains setting it 0.8% off its average median price target of $14.99 for the next 12 months. It is also 67.6% off the consensus price target high of $16.48 offered by 8 analysts, but current levels are 10.85% higher than the price target low of $5.99 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $5.34, the stock is 16.99% and 15.41% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.34 million and changing 17.62% at the moment leaves the stock 0.52% off its SMA200. NCNA registered 1.91% gain for a year compared to 6-month loss of 0.95%. The firm has a 50-day simple moving average (SMA 50) of $4.59 and a 200-day simple moving average (SMA200) of $5.10.
The stock witnessed a 13.62% gain in the last 1 month and extending the period to 3 months gives it a 5.12%, and is 17.36% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.73% over the week and 5.97% over the month.
Distance from 52-week low is 40.16% and -49.58% from its 52-week high.
NuCana plc (NCNA) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for NuCana plc (NCNA) is a “Buy”. 8 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 8 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
NuCana plc is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$16.16.The EPS is expected to shrink by -53.50% this year.
NuCana plc (NCNA) Top Institutional Holders
32 institutions hold shares in NuCana plc (NCNA), with 210.3k shares held by insiders accounting for 0.41% while institutional investors hold 53.93% of the company’s shares. The shares outstanding are 35.09M, and float is at 32.48M with Short Float at 0.18%. Institutions hold 53.71% of the Float.
The top institutional shareholder in the company is Sofinnova Investments, Inc. with over 8.0 million shares valued at $41.36 million. The investor’s holdings represent 24.63% of the NCNA Shares outstanding. As of Sep 29, 2020, the second largest holder is Capital Research Global Investors with 4.58 million shares valued at $23.68 million to account for 14.11% of the shares outstanding. The other top investors are Capital International Investors which holds 4.42 million shares representing 13.60% and valued at over $22.84 million, while Abingworth, LLP holds 10.26% of the shares totaling 3.33 million with a market value of $17.23 million.
NuCana plc (NCNA): Who are the competitors?
The company’s main competitors (and peers) include Pieris Pharmaceuticals Inc. (PIRS) that is trading -16.82% down over the past 12 months. Short interest in the company’s stock has fallen -108.47% from the last report on Nov 12, 2020 to stand at a total of 0.12 million short shares sold with a short interest ratio of 0.33.